Moderna's massive covid vaccine sales and prepayments left it with $18.2 billion in cash at the end of 2022, but that balance is steadily shrinking due to previous share repurchases (more than $5 ...

As the company invests heavily in expanding its non-COVID mRNA vaccine pipeline, the OpenAI partnership positions it to leverage AI’s full potential in accelerating drug development.

Moderna (NASDAQ: MRNA), the next-generation healthcare company most famous for developing the Spikevax coronavirus vaccine, was an uncharacteristically popular stock.

S&P 500 surges in H1 2025; explore AI leaders & ETFs for H2. Click to learn more about stocks to avoid and tips to navigate ...

All three major indexes are headed for outsized monthly gains Stock futures look ready to end the month on a high note. After Friday's flourish despite trade tensions with Canada, S&P 500 Index (SPX) ...